智通财经网·2026-01-09 08:47Core Viewpoint - Shanghai Pharmaceuticals (601607.SH) announced that its subsidiary, Shanghai Shiyou Zhongxi Pharmaceutical Co., Ltd., received a drug registration certificate from the National Medical Products Administration for its oral solution of Pyridostigmine Bromide, which is approved for production [1] Group 1 - The oral solution of Pyridostigmine Bromide is used for the treatment of myasthenia gravis and was originally developed by BAUSCH, first launched in the United States in 1965 [1] - Shanghai Shiyou submitted the registration application for this drug to the National Medical Products Administration in April 2024, which has been accepted [1] - As of the announcement date, the company has invested approximately RMB 2.3174 million in research and development for this drug [1] Group 2 - There are currently no other companies in China that have this drug listed for sale [1]